Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

BHADRESH PATEL

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1003913252
CMS profile
226942
Location
BEVERLY HILLS, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$1,137.72

67 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,137.72 67

By paying entity

PY2021 · entire year · sorted by reported total

Page 1 of 2; records 1–50 of 67 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

BHADRESH PATEL

NPI 1003913252 · CMS profile ID 226942

Allopathic & Osteopathic Physicians / Internal Medicine

BEVERLY HILLS, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 2; records 1–50 of 67 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1003913252?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
BHADRESH PATEL, NPI 1003913252, CMS profile ID 226942. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 67 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1003913252?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). BHADRESH PATEL, NPI 1003913252, CMS profile ID 226942. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 67 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1003913252?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
BHADRESH PATEL, NPI 1003913252, CMS profile ID 226942, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 2; records 1–50 of 67 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1003913252?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

67 matching records · $1,137.72 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 67 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–50 of 67.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Amarin Pharma Inc. $22.5512/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815038503 CMS
AbbVie Inc. $25.0212/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795531610 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $24.8312/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763685686 CMS
Xeris Pharmaceuticals, Inc. $22.6212/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 837439313 CMS
AbbVie Inc. $14.2611/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795531603 CMS
Janssen Pharmaceuticals, Inc $14.0711/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788928363 CMS
Lilly USA, LLC $11.7911/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818973161 CMS
Xeris Pharmaceuticals, Inc. $27.0611/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 837439309 CMS
AbbVie Inc. $8.8611/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795531597 CMS
Novo Nordisk Inc $13.7011/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810812369 CMS
Janssen Pharmaceuticals, Inc $14.8211/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788928365 CMS
AbbVie Inc. $16.4611/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795531591 CMS
AbbVie Inc. $4.4610/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795531585 CMS
Sunovion Pharmaceuticals Inc. $17.8110/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821728053 CMS
AbbVie Inc. $18.9810/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795531579 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $17.1610/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763685688 CMS
Amarin Pharma Inc. $19.6810/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815447713 CMS
AbbVie Inc. $15.0609/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795531573 CMS
GlaxoSmithKline, LLC. $15.6409/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802095685 CMS
Astellas Pharma US Inc $18.3709/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821485485 CMS
Amgen Inc. $16.1709/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826302805 CMS
Janssen Pharmaceuticals, Inc $12.7609/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788928361 CMS
Novartis Pharmaceuticals Corporation $20.7509/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813146777 CMS
Amarin Pharma Inc. $24.5009/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815145143 CMS
Novo Nordisk Inc $20.7008/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811631441 CMS
Novartis Pharmaceuticals Corporation $18.5308/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813146773 CMS
GlaxoSmithKline, LLC. $15.3008/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802807387 CMS
Amarin Pharma Inc. $21.8507/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815038511 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $20.0807/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763685690 CMS
Amarin Pharma Inc. $21.2606/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815447717 CMS
Janssen Pharmaceuticals, Inc $11.6506/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788928359 CMS
Novartis Pharmaceuticals Corporation $14.0406/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813146769 CMS
PFIZER INC. $13.7206/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833569933 CMS
Sunovion Pharmaceuticals Inc. $21.4106/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821616797 CMS
Abbott Laboratories $15.7306/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815527637 CMS
Novo Nordisk Inc $14.5206/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811718033 CMS
Novo Nordisk Inc $16.0606/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811341140 CMS
Astellas Pharma US Inc $16.6405/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821485479 CMS
Amgen Inc. $21.4005/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826302801 CMS
Amgen Inc. $16.6605/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825180217 CMS
AbbVie Inc. $21.8005/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795531567 CMS
Amarin Pharma Inc. $16.7405/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815038507 CMS
Teva Pharmaceuticals USA, Inc. $14.9105/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839625431 CMS
Novartis Pharmaceuticals Corporation $15.1904/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813146765 CMS
AstraZeneca Pharmaceuticals LP $16.1304/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830239199 CMS
Astellas Pharma US Inc $17.2604/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821485471 CMS
Abbott Laboratories $12.9004/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815453679 CMS
Biogen, Inc. $15.7903/31/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827758561 CMS
Novartis Pharmaceuticals Corporation $17.6103/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813146761 CMS
Lilly USA, LLC $14.3503/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818979177 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,622.73 32
PY2020 $547.52 37
PY2021 $1,137.72 67
PY2022 $676.49 44
PY2023 $599.21 34
PY2024 $518.32 33
PY2025 $749.06 42

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $472,003.52 172
PY2024 Principal investigator $421,638.32 23
PY2023 Principal investigator $317,080.95 398
PY2022 Principal investigator $272,453.35 534
PY2020 Principal investigator $3,172.98 4
PY2019 Principal investigator $1,202.28 5

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

534 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ModernaTX, Inc. $522.45 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650733
Principal investigator 1 ModernaTX, Inc. $14.58 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650735
Principal investigator 1 ModernaTX, Inc. $3,213.67 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650737
Principal investigator 1 ModernaTX, Inc. $14.58 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650755
Principal investigator 1 ModernaTX, Inc. $522.45 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650757
Principal investigator 1 ModernaTX, Inc. $14.58 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650775
Principal investigator 1 ModernaTX, Inc. $14.58 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650777
Principal investigator 1 ModernaTX, Inc. $765.45 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650779
Principal investigator 1 ModernaTX, Inc. $522.45 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650781
Principal investigator 1 ModernaTX, Inc. $522.45 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650801
Principal investigator 1 ModernaTX, Inc. $14.58 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650803
Principal investigator 1 ModernaTX, Inc. $14.58 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650805
Principal investigator 1 ModernaTX, Inc. $14.58 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650807
Principal investigator 1 ModernaTX, Inc. $14.58 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650819
Principal investigator 1 ModernaTX, Inc. $14.58 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650821
Principal investigator 1 ModernaTX, Inc. $522.45 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650823
Principal investigator 1 ModernaTX, Inc. $522.45 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650825
Principal investigator 1 ModernaTX, Inc. $765.45 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650827
Principal investigator 1 ModernaTX, Inc. $522.45 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650829
Principal investigator 1 ModernaTX, Inc. $14.58 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650831
Principal investigator 1 ModernaTX, Inc. $14.58 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650845
Principal investigator 1 ModernaTX, Inc. $14.58 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650847
Principal investigator 1 ModernaTX, Inc. $522.45 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650863
Principal investigator 1 ModernaTX, Inc. $14.58 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650865
Principal investigator 1 ModernaTX, Inc. $765.45 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650867
Principal investigator 1 ModernaTX, Inc. $14.58 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650869
Principal investigator 1 ModernaTX, Inc. $14.58 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650871
Principal investigator 1 ModernaTX, Inc. $14.58 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650903
Principal investigator 1 ModernaTX, Inc. $14.58 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650905
Principal investigator 1 ModernaTX, Inc. $14.58 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650907
Principal investigator 1 ModernaTX, Inc. $14.58 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650909
Principal investigator 1 ModernaTX, Inc. $14.58 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650911
Principal investigator 1 ModernaTX, Inc. $14.58 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650913
Principal investigator 1 ModernaTX, Inc. $14.58 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650915
Principal investigator 1 ModernaTX, Inc. $522.45 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650917
Principal investigator 1 ModernaTX, Inc. $14.58 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650919
Principal investigator 1 ModernaTX, Inc. $14.58 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650943
Principal investigator 1 ModernaTX, Inc. $14.58 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650945
Principal investigator 1 ModernaTX, Inc. $14.58 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650947
Principal investigator 1 ModernaTX, Inc. $765.45 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650949
Principal investigator 1 ModernaTX, Inc. $3,213.67 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650953
Principal investigator 1 ModernaTX, Inc. $14.58 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650955
Principal investigator 1 ModernaTX, Inc. $522.45 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650957
Principal investigator 1 ModernaTX, Inc. $14.58 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650959
Principal investigator 1 ModernaTX, Inc. $522.45 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650961
Principal investigator 1 ModernaTX, Inc. $522.45 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650963
Principal investigator 1 ModernaTX, Inc. $14.58 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650987
Principal investigator 1 ModernaTX, Inc. $3,213.67 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650989
Principal investigator 1 ModernaTX, Inc. $14.58 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650991
Principal investigator 1 ModernaTX, Inc. $522.45 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650993
Principal investigator 1 ModernaTX, Inc. $14.58 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651019
Principal investigator 1 ModernaTX, Inc. $522.45 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651021
Principal investigator 1 ModernaTX, Inc. $3,213.67 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651023
Principal investigator 1 ModernaTX, Inc. $3,213.67 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651025
Principal investigator 1 ModernaTX, Inc. $14.58 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651027
Principal investigator 1 ModernaTX, Inc. $14.58 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651047
Principal investigator 1 ModernaTX, Inc. $522.45 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651049
Principal investigator 1 ModernaTX, Inc. $14.58 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651051
Principal investigator 1 ModernaTX, Inc. $14.58 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651053
Principal investigator 1 ModernaTX, Inc. $14.58 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651055
Principal investigator 1 ModernaTX, Inc. $14.58 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651057
Principal investigator 1 ModernaTX, Inc. $522.45 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651071
Principal investigator 1 ModernaTX, Inc. $14.58 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651073
Principal investigator 1 ModernaTX, Inc. $522.45 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651075
Principal investigator 1 ModernaTX, Inc. $14.58 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651077
Principal investigator 1 ModernaTX, Inc. $14.58 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651079
Principal investigator 1 ModernaTX, Inc. $3,213.67 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651081
Principal investigator 1 ModernaTX, Inc. $522.45 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651099
Principal investigator 1 ModernaTX, Inc. $14.58 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651101
Principal investigator 1 ModernaTX, Inc. $14.58 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651103
Principal investigator 1 ModernaTX, Inc. $14.58 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651105
Principal investigator 1 ModernaTX, Inc. $14.58 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651107
Principal investigator 1 ModernaTX, Inc. $522.45 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651121
Principal investigator 1 ModernaTX, Inc. $14.58 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651123
Principal investigator 1 ModernaTX, Inc. $14.58 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651145
Principal investigator 1 ModernaTX, Inc. $765.45 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651147
Principal investigator 1 ModernaTX, Inc. $765.45 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651149
Principal investigator 1 ModernaTX, Inc. $522.45 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651169
Principal investigator 1 ModernaTX, Inc. $14.58 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651171
Principal investigator 1 ModernaTX, Inc. $14.58 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651173
Principal investigator 1 ModernaTX, Inc. $522.45 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651175
Principal investigator 1 ModernaTX, Inc. $765.45 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651177
Principal investigator 1 ModernaTX, Inc. $765.45 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651179
Principal investigator 1 ModernaTX, Inc. $2,138.40 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651181
Principal investigator 1 ModernaTX, Inc. $765.45 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651205
Principal investigator 1 ModernaTX, Inc. $14.58 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651207
Principal investigator 1 ModernaTX, Inc. $14.58 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651209
Principal investigator 1 ModernaTX, Inc. $522.45 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651211
Principal investigator 1 ModernaTX, Inc. $14.58 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651213
Principal investigator 1 ModernaTX, Inc. $522.45 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651215
Principal investigator 1 ModernaTX, Inc. $14.58 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651217
Principal investigator 1 ModernaTX, Inc. $3,213.67 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651235
Principal investigator 1 ModernaTX, Inc. $522.45 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651237
Principal investigator 1 ModernaTX, Inc. $14.58 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651239
Principal investigator 1 ModernaTX, Inc. $522.45 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651241
Principal investigator 1 ModernaTX, Inc. $522.45 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651243
Principal investigator 1 ModernaTX, Inc. $14.58 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651245
Principal investigator 1 ModernaTX, Inc. $14.58 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651247
Principal investigator 1 ModernaTX, Inc. $765.45 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651249
Principal investigator 1 ModernaTX, Inc. $14.58 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651251
Principal investigator 1 ModernaTX, Inc. $14.58 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651253
Principal investigator 1 ModernaTX, Inc. $765.45 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651259
Principal investigator 1 ModernaTX, Inc. $14.58 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651305
Principal investigator 1 ModernaTX, Inc. $14.58 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651307
Principal investigator 1 ModernaTX, Inc. $14.58 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651309
Principal investigator 1 ModernaTX, Inc. $14.58 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651311
Principal investigator 1 ModernaTX, Inc. $522.45 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651313
Principal investigator 1 ModernaTX, Inc. $765.45 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651315
Principal investigator 1 ModernaTX, Inc. $522.45 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651317
Principal investigator 1 ModernaTX, Inc. $522.45 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651319
Principal investigator 1 ModernaTX, Inc. $522.45 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651349
Principal investigator 1 ModernaTX, Inc. $14.58 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651351
Principal investigator 1 ModernaTX, Inc. $1,891.75 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651353
Principal investigator 1 ModernaTX, Inc. $14.58 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651355
Principal investigator 1 ModernaTX, Inc. $14.58 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651357
Principal investigator 1 ModernaTX, Inc. $14.58 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651383
Principal investigator 1 ModernaTX, Inc. $14.58 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651385
Principal investigator 1 ModernaTX, Inc. $14.58 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651387
Principal investigator 1 ModernaTX, Inc. $522.45 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651389
Principal investigator 1 ModernaTX, Inc. $14.58 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651391
Principal investigator 1 ModernaTX, Inc. $14.58 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651397
Principal investigator 1 ModernaTX, Inc. $522.45 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651399
Principal investigator 1 ModernaTX, Inc. $3,213.67 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651401
Principal investigator 1 ModernaTX, Inc. $3,213.67 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651423
Principal investigator 1 ModernaTX, Inc. $522.45 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651425
Principal investigator 1 ModernaTX, Inc. $14.58 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651427
Principal investigator 1 ModernaTX, Inc. $522.45 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651429
Principal investigator 1 ModernaTX, Inc. $14.58 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651431
Principal investigator 1 ModernaTX, Inc. $765.45 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651433
Principal investigator 1 ModernaTX, Inc. $14.58 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651435
Principal investigator 1 ModernaTX, Inc. $765.45 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651447
Principal investigator 1 ModernaTX, Inc. $14.58 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651449
Principal investigator 1 ModernaTX, Inc. $14.58 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651473
Principal investigator 1 ModernaTX, Inc. $522.45 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651475
Principal investigator 1 ModernaTX, Inc. $522.45 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651477
Principal investigator 1 ModernaTX, Inc. $14.58 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651479
Principal investigator 1 ModernaTX, Inc. $14.58 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651515
Principal investigator 1 ModernaTX, Inc. $14.58 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651517
Principal investigator 1 ModernaTX, Inc. $14.58 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651519
Principal investigator 1 ModernaTX, Inc. $14.58 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651537
Principal investigator 1 ModernaTX, Inc. $14.58 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651539
Principal investigator 1 ModernaTX, Inc. $14.58 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651541
Principal investigator 1 ModernaTX, Inc. $14.58 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651543
Principal investigator 1 ModernaTX, Inc. $14.58 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651657
Principal investigator 1 ModernaTX, Inc. $765.45 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651659
Principal investigator 1 ModernaTX, Inc. $14.58 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651677
Principal investigator 1 ModernaTX, Inc. $14.58 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651679
Principal investigator 1 ModernaTX, Inc. $14.58 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651681
Principal investigator 1 ModernaTX, Inc. $14.58 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651683
Principal investigator 1 ModernaTX, Inc. $14.58 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651703
Principal investigator 1 ModernaTX, Inc. $14.58 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651705
Principal investigator 1 ModernaTX, Inc. $14.58 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651707
Principal investigator 1 ModernaTX, Inc. $14.58 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651711
Principal investigator 1 ModernaTX, Inc. $522.45 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651723
Principal investigator 1 ModernaTX, Inc. $522.45 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651725
Principal investigator 1 ModernaTX, Inc. $14.58 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651727
Principal investigator 1 ModernaTX, Inc. $14.58 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651729
Principal investigator 1 ModernaTX, Inc. $14.58 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651731
Principal investigator 1 ModernaTX, Inc. $3,213.67 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651733
Principal investigator 1 ModernaTX, Inc. $3,213.67 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651735
Principal investigator 1 ModernaTX, Inc. $522.45 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651737
Principal investigator 1 ModernaTX, Inc. $765.45 12/16/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963651739
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648117
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648119
Principal investigator 1 ModernaTX, Inc. $765.45 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648121
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648123
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648129
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648131
Principal investigator 1 ModernaTX, Inc. $765.45 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648133
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648135
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648311
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648313
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648315
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648317
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648319
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648321
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648323
Principal investigator 1 ModernaTX, Inc. $3,213.67 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648325
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648327
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648329
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648331
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648361
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648415
Principal investigator 1 ModernaTX, Inc. $765.45 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648417
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648457
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648459
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648461
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648463
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648497
Principal investigator 1 ModernaTX, Inc. $3,213.67 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648499
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648501
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648503
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648537
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648539
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648541
Principal investigator 1 ModernaTX, Inc. $765.45 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648543
Principal investigator 1 ModernaTX, Inc. $765.45 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648571
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648573
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648575
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648577
Principal investigator 1 ModernaTX, Inc. $765.45 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648579
Principal investigator 1 ModernaTX, Inc. $765.45 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648581
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648583
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648585
Principal investigator 1 ModernaTX, Inc. $765.45 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648619
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648621
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648623
Principal investigator 1 ModernaTX, Inc. $765.45 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648635
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648637
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648639
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648641
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648643
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648645
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648647
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648649
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648651
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648689
Principal investigator 1 ModernaTX, Inc. $2,138.40 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648691
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648693
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648695
Principal investigator 1 ModernaTX, Inc. $3,213.67 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648697
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648699
Principal investigator 1 ModernaTX, Inc. $3,213.67 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648701
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648711
Principal investigator 1 ModernaTX, Inc. $3,213.67 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648713
Principal investigator 1 ModernaTX, Inc. $765.45 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648715
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648717
Principal investigator 1 ModernaTX, Inc. $1,891.75 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648719
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648749
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648751
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648753
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648755
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648757
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648759
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648761
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648801
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648803
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648805
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648807
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648809
Principal investigator 1 ModernaTX, Inc. $765.45 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648811
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648813
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648815
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648817
Principal investigator 1 ModernaTX, Inc. $765.45 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648819
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648863
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648865
Principal investigator 1 ModernaTX, Inc. $3,213.67 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648867
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648869
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648871
Principal investigator 1 ModernaTX, Inc. $765.45 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648921
Principal investigator 1 ModernaTX, Inc. $765.45 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648923
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648925
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648947
Principal investigator 1 ModernaTX, Inc. $3,213.67 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648949
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648951
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648975
Principal investigator 1 ModernaTX, Inc. $765.45 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649019
Principal investigator 1 ModernaTX, Inc. $765.45 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649021
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649023
Principal investigator 1 ModernaTX, Inc. $765.45 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649025
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649027
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649029
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649031
Principal investigator 1 ModernaTX, Inc. $3,213.67 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649033
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649035
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649037
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649063
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649065
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649093
Principal investigator 1 ModernaTX, Inc. $1,891.75 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649095
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649097
Principal investigator 1 ModernaTX, Inc. $3,213.67 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649099
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649101
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649103
Principal investigator 1 ModernaTX, Inc. $765.45 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649105
Principal investigator 1 ModernaTX, Inc. $3,213.67 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649107
Principal investigator 1 ModernaTX, Inc. $3,213.67 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649109
Principal investigator 1 ModernaTX, Inc. $765.45 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649165
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649167
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649169
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649171
Principal investigator 1 ModernaTX, Inc. $3,213.67 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649201
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649203
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649205
Principal investigator 1 ModernaTX, Inc. $765.45 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649207
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649253
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649255
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649257
Principal investigator 1 ModernaTX, Inc. $3,213.67 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649259
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649263
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649265
Principal investigator 1 ModernaTX, Inc. $765.45 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649267
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649269
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649319
Principal investigator 1 ModernaTX, Inc. $765.45 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649321
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649323
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649325
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649327
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649329
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649365
Principal investigator 1 ModernaTX, Inc. $765.45 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649369
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649373
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649381
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649385
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649389
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649393
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649397
Principal investigator 1 ModernaTX, Inc. $765.45 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649473
Principal investigator 1 ModernaTX, Inc. $765.45 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649477
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649479
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649481
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649483
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649485
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649487
Principal investigator 1 ModernaTX, Inc. $2,138.40 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649489
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649529
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649531
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649533
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649561
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649563
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649565
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649567
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649595
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649597
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649621
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649623
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649625
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649627
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649629
Principal investigator 1 ModernaTX, Inc. $3,213.67 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649657
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649659
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649661
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649689
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649691
Principal investigator 1 ModernaTX, Inc. $3,213.67 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649693
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649695
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649719
Principal investigator 1 ModernaTX, Inc. $736.60 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649721
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649723
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649729
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649731
Principal investigator 1 ModernaTX, Inc. $765.45 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649733
Principal investigator 1 ModernaTX, Inc. $3,213.67 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649767
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649797
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649799
Principal investigator 1 ModernaTX, Inc. $3,213.67 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649801
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649803
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649805
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649807
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649809
Principal investigator 1 ModernaTX, Inc. $765.45 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649811
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649855
Principal investigator 1 ModernaTX, Inc. $3,213.67 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649857
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649883
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649885
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649887
Principal investigator 1 ModernaTX, Inc. $3,213.67 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649889
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649891
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649893
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649895
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649901
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649903
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649905
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649919
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649921
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649923
Principal investigator 1 ModernaTX, Inc. $3,213.67 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649925
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649927
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649967
Principal investigator 1 ModernaTX, Inc. $765.45 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649969
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649971
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649973
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649975
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649977
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649979
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649985
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650019
Principal investigator 1 ModernaTX, Inc. $3,213.67 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650021
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650023
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650025
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650027
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650029
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650031
Principal investigator 1 ModernaTX, Inc. $2,138.40 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650033
Principal investigator 1 ModernaTX, Inc. $765.45 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650091
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650093
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650095
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650097
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650099
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650101
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650103
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650105
Principal investigator 1 ModernaTX, Inc. $3,213.67 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650123
Principal investigator 1 ModernaTX, Inc. $3,213.67 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650125
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650159
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650161
Principal investigator 1 ModernaTX, Inc. $3,213.67 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650163
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650165
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650167
Principal investigator 1 ModernaTX, Inc. $3,213.67 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650169
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650171
Principal investigator 1 ModernaTX, Inc. $765.45 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650173
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650209
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650211
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650237
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650239
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650241
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650243
Principal investigator 1 ModernaTX, Inc. $3,213.67 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650245
Principal investigator 1 ModernaTX, Inc. $3,213.67 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650247
Principal investigator 1 ModernaTX, Inc. $1,891.75 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650249
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650285
Principal investigator 1 ModernaTX, Inc. $3,213.67 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650287
Principal investigator 1 ModernaTX, Inc. $765.45 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650289
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650291
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650293
Principal investigator 1 ModernaTX, Inc. $3,213.67 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650295
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650297
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650299
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650341
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650343
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650371
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650373
Principal investigator 1 ModernaTX, Inc. $765.45 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650395
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650415
Principal investigator 1 ModernaTX, Inc. $3,213.67 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650459
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650487
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650489
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650491
Principal investigator 1 ModernaTX, Inc. $765.45 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650493
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650495
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650497
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650499
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650501
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650503
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650505
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650507
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650509
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650523
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650525
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650527
Principal investigator 1 ModernaTX, Inc. $765.45 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650593
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650595
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650597
Principal investigator 1 ModernaTX, Inc. $765.45 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650621
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650623
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650625
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650627
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650675
Principal investigator 1 ModernaTX, Inc. $14.58 11/21/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650679
Principal investigator 1 ModernaTX, Inc. $14.58 11/17/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648139
Principal investigator 1 ModernaTX, Inc. $14.58 11/17/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648141
Principal investigator 1 ModernaTX, Inc. $14.58 11/17/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648143
Principal investigator 1 ModernaTX, Inc. $14.58 11/17/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648145
Principal investigator 1 ModernaTX, Inc. $14.58 11/17/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648291
Principal investigator 1 ModernaTX, Inc. $3,213.67 11/17/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648363
Principal investigator 1 ModernaTX, Inc. $14.58 11/17/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648419
Principal investigator 1 ModernaTX, Inc. $14.58 11/17/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648421
Principal investigator 1 ModernaTX, Inc. $14.58 11/17/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648505
Principal investigator 1 ModernaTX, Inc. $3,213.67 11/17/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648507
Principal investigator 1 ModernaTX, Inc. $14.58 11/17/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648515
Principal investigator 1 ModernaTX, Inc. $14.58 11/17/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648517
Principal investigator 1 ModernaTX, Inc. $14.58 11/17/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648519
Principal investigator 1 ModernaTX, Inc. $14.58 11/17/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648545
Principal investigator 1 ModernaTX, Inc. $14.58 11/17/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648547
Principal investigator 1 ModernaTX, Inc. $14.58 11/17/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648587
Principal investigator 1 ModernaTX, Inc. $765.45 11/17/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648653
Principal investigator 1 ModernaTX, Inc. $14.58 11/17/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648655
Principal investigator 1 ModernaTX, Inc. $14.58 11/17/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648657
Principal investigator 1 ModernaTX, Inc. $14.58 11/17/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648659
Principal investigator 1 ModernaTX, Inc. $14.58 11/17/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648661
Principal investigator 1 ModernaTX, Inc. $14.58 11/17/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648721
Principal investigator 1 ModernaTX, Inc. $14.58 11/17/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648723
Principal investigator 1 ModernaTX, Inc. $765.45 11/17/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648821
Principal investigator 1 ModernaTX, Inc. $14.58 11/17/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648823
Principal investigator 1 ModernaTX, Inc. $14.58 11/17/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648873
Principal investigator 1 ModernaTX, Inc. $14.58 11/17/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648875
Principal investigator 1 ModernaTX, Inc. $14.58 11/17/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648877
Principal investigator 1 ModernaTX, Inc. $14.58 11/17/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648879
Principal investigator 1 ModernaTX, Inc. $14.58 11/17/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648953
Principal investigator 1 ModernaTX, Inc. $14.58 11/17/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648955
Principal investigator 1 ModernaTX, Inc. $3,213.67 11/17/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963648991
Principal investigator 1 ModernaTX, Inc. $3,213.67 11/17/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649039
Principal investigator 1 ModernaTX, Inc. $14.58 11/17/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649067
Principal investigator 1 ModernaTX, Inc. $14.58 11/17/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649111
Principal investigator 1 ModernaTX, Inc. $14.58 11/17/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649113
Principal investigator 1 ModernaTX, Inc. $3,213.67 11/17/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649115
Principal investigator 1 ModernaTX, Inc. $14.58 11/17/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649131
Principal investigator 1 ModernaTX, Inc. $765.45 11/17/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649173
Principal investigator 1 ModernaTX, Inc. $14.58 11/17/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649175
Principal investigator 1 ModernaTX, Inc. $3,213.67 11/17/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649209
Principal investigator 1 ModernaTX, Inc. $3,213.67 11/17/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649211
Principal investigator 1 ModernaTX, Inc. $3,213.67 11/17/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649423
Principal investigator 1 ModernaTX, Inc. $14.58 11/17/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649491
Principal investigator 1 ModernaTX, Inc. $14.58 11/17/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649599
Principal investigator 1 ModernaTX, Inc. $14.58 11/17/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649665
Principal investigator 1 ModernaTX, Inc. $14.58 11/17/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649667
Principal investigator 1 ModernaTX, Inc. $14.58 11/17/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649725
Principal investigator 1 ModernaTX, Inc. $14.58 11/17/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649735
Principal investigator 1 ModernaTX, Inc. $14.58 11/17/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649737
Principal investigator 1 ModernaTX, Inc. $14.58 11/17/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649769
Principal investigator 1 ModernaTX, Inc. $14.58 11/17/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649771
Principal investigator 1 ModernaTX, Inc. $14.58 11/17/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649813
Principal investigator 1 ModernaTX, Inc. $14.58 11/17/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649815
Principal investigator 1 ModernaTX, Inc. $14.58 11/17/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649929
Principal investigator 1 ModernaTX, Inc. $14.58 11/17/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649931
Principal investigator 1 ModernaTX, Inc. $14.58 11/17/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649933
Principal investigator 1 ModernaTX, Inc. $14.58 11/17/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649939
Principal investigator 1 ModernaTX, Inc. $14.58 11/17/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649941
Principal investigator 1 ModernaTX, Inc. $765.45 11/17/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649991
Principal investigator 1 ModernaTX, Inc. $3,213.67 11/17/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649993
Principal investigator 1 ModernaTX, Inc. $14.58 11/17/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650127
Principal investigator 1 ModernaTX, Inc. $14.58 11/17/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650141
Principal investigator 1 ModernaTX, Inc. $14.58 11/17/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650177
Principal investigator 1 ModernaTX, Inc. $14.58 11/17/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650179
Principal investigator 1 ModernaTX, Inc. $14.58 11/17/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650255
Principal investigator 1 ModernaTX, Inc. $14.58 11/17/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650301
Principal investigator 1 ModernaTX, Inc. $14.58 11/17/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650303
Principal investigator 1 ModernaTX, Inc. $3,213.67 11/17/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650305
Principal investigator 1 ModernaTX, Inc. $14.58 11/17/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650511
Principal investigator 1 ModernaTX, Inc. $14.58 11/17/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650529
Principal investigator 1 ModernaTX, Inc. $14.58 11/17/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650531
Principal investigator 1 ModernaTX, Inc. $14.58 11/17/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650533
Principal investigator 1 ModernaTX, Inc. $3,213.67 11/17/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650535
Principal investigator 1 ModernaTX, Inc. $14.58 11/17/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650563
Principal investigator 1 ModernaTX, Inc. $14.58 11/17/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650565
Principal investigator 1 ModernaTX, Inc. $14.58 11/17/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650677
Principal investigator 1 ModernaTX, Inc. $3,213.67 11/17/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650703
Principal investigator 1 ModernaTX, Inc. $500.00 11/10/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963649663
Principal investigator 1 ModernaTX, Inc. $8,000.00 11/10/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650175
Principal investigator 1 ModernaTX, Inc. $2,000.00 11/10/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963650629
Principal investigator 1 ModernaTX, Inc. $6,360.00 11/10/2022 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A PHASE 3, RANDOMIZED, OBSERVER-BLIND, ACTIVE-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1010 CANDIDATE SEASONAL INFLUENZA VACCINE IN ADULTS 50 YEARS AND OLDER No dispute reported 06/30/2026 963651743
Principal investigator 1 ModernaTX, Inc. $498.00 09/13/2022 Non-covered Recipient Entity
ELITE RESEARCH NETWORK - NATURE COAST CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963294745